Rani Therapeutics Holdings (RANI) Amortization of Deferred Charges (2022 - 2026)

Rani Therapeutics Holdings' Amortization of Deferred Charges history runs 5 years deep, the most recent figure standing at $477000.0 for Q1 2026.

• In Q1 2026, Amortization of Deferred Charges rose 722.41% year-over-year to $477000.0; the TTM figure through Mar 2026 stood at $626000.0 (down 57.96% YoY), while the FY2025 annual figure was $207000.0, down 88.56% from the prior year.
• Amortization of Deferred Charges for Q1 2026 stood at $477000.0, up from -$1.2 million in the prior quarter.
• The five-year high for Amortization of Deferred Charges was $1.6 million in Q4 2024, with the low at -$1.2 million in Q4 2025.
• The 5-year median for Amortization of Deferred Charges is $58000.0 (2023), against an average of $232600.0.
• The sharpest annual moves came in 2023 and 2025: Amortization of Deferred Charges surged 3394.74% in 2023, then sank 174.62% in 2025.
• Rani Therapeutics Holdings' Amortization of Deferred Charges stood at $745000.0 in 2022, then sank by 173.56% to -$548000.0 in 2023, then surged by 398.36% to $1.6 million in 2024, then tumbled by 174.62% to -$1.2 million in 2025, then jumped by 139.1% to $477000.0 in 2026.
• Business Quant data shows RANI's Amortization of Deferred Charges at $477000.0 in Q1 2026, -$1.2 million in Q4 2025, and $1.3 million in Q3 2025.